Clinical Trial Detail

NCT ID NCT02337530
Title Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors NCIC Clinical Trials Group
Indications

lung non-small cell carcinoma

Therapies

Selumetinib

Cisplatin + Pemetrexed Disodium

Age Groups: adult

No variant requirements are available.